REPUBLIQUE
ET CANTON
DE GENEVE

NovImmune, an antibody-focused research and development biotech company, announced that it successfully entered into an exclusive licensing agreement with Genentech Inc. a member of the Roche Group for a proprietary anti-IL-17 fully human monoclonal antibody, and access to back-up antibodies. Recently, the IL-17 signaling pathway has received significant academic and corporate interest as its manipulation may potentially provide new treatment opportunities for major medical conditions.The anti-IL-17 antibody was generated by NovImmune’s research team and is currently in late preclinical development.For more information and full press release, please visit www.novimmune.com